OPKO Health, Inc. (NASDAQ:OPK) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Yvonne Briggs – LHA Investor Relations Phillip Frost – Chairman and Chief Executive Officer Elias Zerhouni – Vice Chairman and President Adam Logal – Chief Financial Officer Conference Call Participants Maury Raycroft – Jefferies Yale Jen – Laidlaw and Company Michael Petusky – Barrington Research Operator Good day, and welcome to the OPKO Health Second Quarter 2024 Financial Results Conference Cal ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024. OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Securities registered pursuant to Section 12(b) of the Act: | --- | --- | |---------------------------------------------------------------------------|------------------------ ...

Exhibit 99.1 OPKO Health Reports Second Quarter 2024 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI (August 7, 2024) – OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and six months ended June 30, 2024. Highlights from the second quarter and recent weeks include the following: ● Enrollment underway in the MDX2001 Phase 1 trial for the treatment of solid tumor cancers. MDX2001, a tetraspecific antibody, is ...

MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) today announced that its Board of Directors has authorized the repurchase of up to $100 million of shares of the Company's common stock. Under the repurchase program, OPKO may repurchase shares of its common stock from time to time through open market purchases, block trades, privately negotiated transactions, accelerated share repurchase transactions and/or pursuant to Rule 10b5-1 plans, in compliance with applicable securities laws an ...

MIAMI, July 17, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) announces it has entered into a $250 million non-dilutive note purchase agreement with HealthCare Royalty (HCRx) secured by OPKO's profit share payments from Pfizer received pursuant to its license agreement relating to NGENLA™, a once-weekly treatment currently marketed to treat pediatric growth hormone deficiency. "This transaction with HCRx allows OPKO to retain a significant portion of NGENLA's profit share payments in the near ter ...

It has been about a month since the last earnings report for OPKO Health (OPK) . Shares have added about 12.8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is OPKO Health due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. OPKO Health's Q1 Earnings Miss Estimates, Sale ...

OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. For more information, visit www.opko.com. Contacts: LHA Investor Relations Yvonne Briggs, 310-691-7100 ybriggs@lhai.com or Bruce Voss, 310-691-7100 bvoss@lhai.com MIAMI, May 31, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) announced tod ...

OPKO Health, Inc. (OPK) delivered a loss per share of 12 cents in the first quarter of 2024, wider than the year-ago period’s loss of 2 cents per share. The figure missed the Zacks Consensus Estimate of a loss of 9 cents per share by 33.3%.Revenues in DetailOPKO Health registered sales of $173.7 million, down 26.9% year over year. The figure missed the Zacks Consensus Estimate by 5%.Lower revenues from the transfer of intellectual property and others dragged the overall top line.Segmental RevenuesOPKO Healt ...

For the quarter ended March 2024, OPKO Health (OPK) reported revenue of $173.7 million, down 26.9% over the same period last year. EPS came in at -$0.12, compared to -$0.02 in the year-ago quarter.The reported revenue represents a surprise of -5.00% over the Zacks Consensus Estimate of $182.84 million. With the consensus EPS estimate being -$0.09, the EPS surprise was -33.33%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Stre ...

Start Time: 16:30 January 1, 0000 5:21 PM ET OPKO Health, Inc. (NASDAQ:OPK) Q1 2024 Earnings Conference Call May 07, 2024, 16:30 PM ET Company Participants Phil Frost - Chairman and CEO Elias Zerhouni - President and Vice Chairman Adam Logal - SVP and CFO Charles Bishop - CEO, OPKO Renal Gary Nabel - Chief Innovation Officer Yvonne Briggs - LHA IR Conference Call Participants Maury Raycroft - Jefferies Jeff Cohen - Ladenburg Thalmann Company Edward Tenthoff - Piper Sandler Yale Jen - Laidlaw & Company Yi Ch ...